Cold Genesys closes $22M series C

Cold Genesys raised $22 million in a series C round Monday to fund development of its lead immunotherapy, CG0070, which has completed Phase II testing to treat non-muscle invasive bladder cancer (NMIBC).

Cold Genesys Inc. (Santa Ana, Calif.) said new investor ORI Healthcare Fund led the round with participation from Perseverance Capital...